Drug therapy of postprandial hyperglycaemia

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Achieving normal blood glucose levels is a primary goal in diabetes mellitus management.
• Postprandial hyperglycemia (PPHG) is challenging to control and linked to macrovascular complications.
• Newer pharmacologic agents specifically target PPHG.

Purpose of the Study:

• To review and compare novel pharmacologic agents for managing postprandial hyperglycemia (PPHG) in diabetes mellitus.
• To highlight the mechanisms of action and clinical outcomes of drugs targeting PPHG.

Main Methods:

• Review of recent pharmacologic agents targeting PPHG.
• Comparison of insulin lispro, amylin analogues, alpha-glucosidase inhibitors, and meglitinide analogues.
• Analysis of pharmacodynamic profiles and clinical trial data.

Main Results:

• Insulin lispro offers rapid action for PPHG control with fewer hypoglycemic episodes.
• Repaglinide stimulates endogenous insulin secretion to lower postprandial glucose excursions.
• Amylin analogues and alpha-glucosidase inhibitors reduce PPHG by slowing nutrient absorption.

Conclusions:

• Novel agents provide targeted approaches to manage PPHG.
• Improved control of postprandial blood glucose excursions is now achievable for more diabetic patients.
• These advancements facilitate reaching glycemic goals in diabetes management.